Logo

Agendia Gets FDA Clearance for MammaPrint on Agilent Systems

Feb 23, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia has received another clearance for the firm's MammaPrint breast cancer recurrence assay.

The new clearance is for running the test on two additional Agilent microarray scanners and two Agilent Bioanalyzers. Agendia said the additional clearance will expand laboratory capacity to handle the increasing number of MammaPrint, TargetPrint, and BluePrint test results.

Previously, the MammaPrint test was only allowed to be performed at Agendia's lab in Irvine, Calif. The new clearance enables the test to be run in a central laboratory and allows Agendia to also perform the test at its lab in Amsterdam, where the firm is based.

MammaPrint was the first in vitro diagnostic multivariate index assay device approved by the FDA in early 2007.

Filed under

Molecular Diagnostics
Microarrays & Multiplexing
Diagnostics
Regulatory News & FDA Approvals
FDA clearance
microarrays
gene expression arrays
IVDMIA
Agilent
Agendia
Breaking News
The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.